NCT03497624 is a clinical trial of Biospecimens collection in ROS1-fusion Positive Tumor, sponsored by Addario Lung Cancer Medical Institute.

Who is sponsoring NCT03497624?

NCT03497624 is sponsored by Addario Lung Cancer Medical Institute.

What drugs are being tested in NCT03497624?

Interventions in NCT03497624: Biospecimens collection.

What condition does NCT03497624 study?

NCT03497624 studies ROS1-fusion Positive Tumor.

Is NCT03497624 still recruiting?

NCT03497624 is currently completed. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT03497624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors

Completed Last updated 9 September 2020

What this trial tests

trial testing Biospecimens collection in ROS1-fusion Positive Tumor in 5 participants. Completed in 4 September 2020.

Timeline

23 April 2018

Primary endpoint
4 September 2020

4 September 2020

Quick facts

Lead sponsor	Addario Lung Cancer Medical Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5
Start date	23 April 2018
Primary completion	4 September 2020
Estimated completion	4 September 2020
Sites	1 location across United States

Drugs / interventions tested

Biospecimens collection

Conditions studied

ROS1-fusion Positive Tumor — all drugs for ROS1-fusion Positive Tumor →

Sponsor

Addario Lung Cancer Medical Institute

Who can join

18 and older, any sex, with ROS1-fusion Positive Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patient Derived Xenografts (PDXs) are models to study tumor growth, response to anti-cancer therapies, and resistance to anti-cancer therapies. The purpose of this study is to develop up to 24 PDX models for ROS1-fusion driven cancers to be used for research purposes only. That is, these patient derived PDX models will have no immediate benefit to the patient from whom the tumor specimen was obtained. Rather, these PDX models will be used to inform the study of ROS1-fusion driven cancers at large.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.
Arnal-Estapé A, Foggetti G, Starrett JH, Nguyen DX, et al · · 2021 · cited 15× · PMID 34518338 · DOI 10.1101/cshperspect.a037820

Verify or expand the search:

Other Addario Lung Cancer Medical Institute trials

Trials by the same sponsor.

NCT04676386 — Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Add · terminated
NCT03833934 — Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance · completed
NCT03872440 — PDX Models From EGFR Mutant Tumors · withdrawn
NCT03553550 — Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03497624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Addario Lung Cancer Medical Institute
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03497624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing